PMID- 20149981
OWN - NLM
STAT- MEDLINE
DCOM- 20110426
LR  - 20131121
IS  - 1873-1449 (Electronic)
IS  - 1538-4721 (Linking)
VI  - 10
IP  - 1
DP  - 2011 Jan-Feb
TI  - Evaluation of radiobiologic biochemical control in a large permanent prostate 
      brachytherapy population from a single institution using AAPM TG-137 parameters.
PG  - 16-28
LID - 10.1016/j.brachy.2009.12.003 [doi]
AB  - PURPOSE: To re-evaluate prostate implant dosimetry using American Association of 
      Physicists in Medicine Task Group 43 parameters and the radiobiologic approach of 
      American Association of Physicists in Medicine Task Group 137. METHODS AND 
      MATERIALS: Among 1473 consecutive patients implanted with iodine-125 or 
      palladium-103 sources before March 2006, there have been 55 biochemical failures. 
      The dosimetric quality parameter, D(90), was updated according to the 
      radionuclide and dosimetric era of the implant. For each patient, biologically 
      equivalent dose (BED) and tumor control probability (TCP) were calculated from 
      the updated implant D(90) plus any external beam dose using recommended indices 
      and equations. RESULTS: There was no significant difference in BED between 
      biochemical failures and nonfailures, 148+/-27Gy and 145+/-24Gy, respectively 
      (p=0.352). TCP was 0.90+/-0.26 for biochemical failures and 0.93+/-0.21 for 
      nonfailures (p=0.414). Cox regression analysis found that neither BED nor TCP 
      predicted for biochemical control either for the entire population or within each 
      radionuclide-dependent dosimetric era. The only overall predictors of biochemical 
      control were dosimetric era, Gleason score, and percent positive biopsies. 
      Improvements in dosimetric quality over the first 300 patients were evident, but 
      dosimetric era remained a better predictor of biochemical outcome than implant 
      sequence number. CONCLUSION: In a large prostate implant population, dosimetric 
      and derived radiobiologic parameters did not predict for failure. Apparently, too 
      few patients had total BEDs below the level necessary for optimum biochemical 
      control. A learning curve extended over hundreds of patients before plateauing 
      but changes in seed characterization parameters also had a pronounced effect.
CI  - Copyright (c) 2011 American Brachytherapy Society. Published by Elsevier Inc. All 
      rights reserved.
FAU - Butler, Wayne M
AU  - Butler WM
AD  - Schiffler Cancer Center, Wheeling Hospital, 1 Medical Park, Wheeling, WV 26003, 
      USA. wbutler@wheelinghospital.org
FAU - Stewart, Renee R
AU  - Stewart RR
FAU - Merrick, Gregory S
AU  - Merrick GS
LA  - eng
PT  - Journal Article
DEP - 20100211
PL  - United States
TA  - Brachytherapy
JT  - Brachytherapy
JID - 101137600
RN  - 0 (Iodine Radioisotopes)
RN  - 0 (Radioisotopes)
RN  - 5TWQ1V240M (Palladium)
SB  - IM
MH  - Aged
MH  - Brachytherapy/methods/standards
MH  - Humans
MH  - Iodine Radioisotopes/administration & dosage
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Palladium/administration & dosage
MH  - Proportional Hazards Models
MH  - Prostatic Neoplasms/*radiotherapy
MH  - Radioisotopes/administration & dosage
MH  - Radiotherapy Dosage
MH  - Retrospective Studies
MH  - Risk Factors
EDAT- 2010/02/13 06:00
MHDA- 2011/04/27 06:00
CRDT- 2010/02/13 06:00
PHST- 2009/07/29 00:00 [received]
PHST- 2009/12/07 00:00 [revised]
PHST- 2009/12/15 00:00 [accepted]
PHST- 2010/02/13 06:00 [entrez]
PHST- 2010/02/13 06:00 [pubmed]
PHST- 2011/04/27 06:00 [medline]
AID - S1538-4721(09)00370-5 [pii]
AID - 10.1016/j.brachy.2009.12.003 [doi]
PST - ppublish
SO  - Brachytherapy. 2011 Jan-Feb;10(1):16-28. doi: 10.1016/j.brachy.2009.12.003. Epub 
      2010 Feb 11.